

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Simcere Pharmaceutical Group Limited

先聲藥業集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 2096)

PROFIT ALERT

This announcement is made by Simcere Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (“**Directors**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on a preliminary assessment of the Group’s unaudited consolidated management accounts for the six months ended June 30, 2022, it is expected that:

- (i) For the six months ended June 30, 2022, the Group recorded a revenue of approximately RMB2,670 million to RMB2,730 million, representing an increase of approximately 26% to 29% from RMB2,120 million for the same period last year. Such expected increase was mainly attributable to a rapid increase in sales of innovative drugs.
- (ii) For the six months ended June 30, 2022, the Group recorded a profit attributable to equity shareholders of the Company of approximately RMB34 million to RMB94 million, representing a decrease of approximately 83% to 94% from RMB558 million for the same period last year. Such expected decrease was mainly attributable to the following items: (a) the Group recorded a net realized and unrealized loss (before tax) on financial assets at fair value through profit or loss of approximately RMB331 million due to a decrease in the fair value of the investment portfolio held by the Group during this period, and (b) the Group recorded a one-off gain (before tax) of approximately RMB399 million for the same period last year from the disposal of its entire equity interest in Simgene Group Limited.

The Company is still in the process of finalising the interim results of the Group for the six months ended June 30, 2022. The information contained in this announcement is based solely on the preliminary assessment of the Group's unaudited consolidated management accounts for the six months ended June 30, 2022 and is subject to finalisation and other potential adjustments, if any, and has not been reviewed or confirmed by the Group's auditors or the Audit Committee of the Board. Shareholders and potential investors of the Company should refer to the Group's interim results announcement for the six months ended June 30, 2022, which is expected to be published by the end of August 2022.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Simcere Pharmaceutical Group Limited
Mr. Ren Jinsheng
Chairman and Chief Executive Officer

Hong Kong, August 1, 2022

As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director, Mr. WAN Yushan and Mr. TANG Renhong as the executive Directors; Mr. ZHAO John Huan as the non-executive Director; and Mr. SONG Ruilin, Mr. WANG Jianguo and Mr. WANG Xinhua as the independent non-executive Directors.